Glioblastoma (GBM) is the most common primary brain tumor of the adult. Despite existing multimodal aggressive treatment regiments the prognosis of patients with GBM remains very poor. Most patients die within two years after diagnosis. Changes in individual gene expressions frequently accompany malignant cell transformation. Therefore comparative gene expression analyses of tumorous and non-tumorous tissue may help identify genes of significance in gliomagenesis. Epigenetic silencing of tumor suppressor genes is one of important mechanisms of gene inactivation during tumorigenesis. This study attempted to detect genes potentially regulated by promoter methylation in glioblastoma. To this end we analyzed the expression of COX7A1, SPINT1 and KRT81 in glioblastomas and human brain tissue and investigated their relation to promoter methylation of these genes.
We based candidate gene selection on bioinformatics, reverse transcription-polymerase chain reaction (RT-PCR) and bisulfite sequencing. COX7A1, SPINT1 and KRT81 mRNA expression was analyzed in glioblastomas (n = 22) and human brain tissue (n = 2). COX7A1, SPINT1 and KRT81 promoter methylation was analyzed in selected glioblastoma samples, human brain and human lymphocytes by bisulfite sequencing.
We found a differential gene expression of COX7A1, SPINT1 and KRT81 in the glioblastoma samples. Normal fetal and adult brain featured a robust expression of these genes. Analysis of bisulfite-modified DNA of brain tissue confirmed that the SPINT1 promoter had only single scattered methylated CpG-dinucleotides while the CpG-islands of the COX7A1 and KRT81 promoters were abundantly methylated in brain tissue despite robust gene expression.
COX7A1 and KRT81 gene expression is independent of promoter methylation in glioblastoma. The data suggest the possibility of epigenetic regulation of SPINT1 in glioblastoma. Future work should focus on SPINT1 gene function in glial cells to substantiate its potential tumor suppressor gene function in gliomas.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most aggressive form of malignant glioma. It is the most common primary human brain tumor in the adult. Diffuse brain tissue infiltration and molecular tumor cell properties of therapy resistance make treatment of these tumors especially difficult. Despite multimodal therapy with gross total resection in combination with adjuvant radio-and chemotherapy prognosis of patients with GBM remains very poor. Median survival is about one year following diagnosis. The analysis of gene expression and its regulation is one of the most intriguing fields in cancer research. Promoter methylation affects the expression of many genes in normal and cancer tissue and may play an important role in gliomagenesis. Pharmacologic manipulation of glioma cells with the demethylating agent 5'-aza-dC combined with genome wide expression profiling succeeded in unveiling novel candidate genes, which are epigenetically regulated in cancer in general (Yamashita et al., 2002) and in gliomas in particular (Mueller et 
MATERIALS AND METHODS
DNA and RNA isolation 22 glioblastoma samples were obtained from Charité, Campus Virchow Klinikum from patients who underwent surgery in the Department of Neurosurgery and snap frozen. All GBM were histologically diagnosed according to the WHO criteria. Total RNA and DNA were isolated from snap frozen primary glioblastoma tissues using TRIzol (Invitrogen Life Technologies Inc) according to the manufacturer's recommendations. DNA was extracted from snap frozen primary glioblastoma tissues using Genomic DNA from Tissue Kit (Macherey-Nagel) according to the manufacturer's protocol.
Reverse transcription-PCR analysis
For cDNA synthesis 1 μg of total RNA was used for reverse transcription (random primer) using SuperScriptTM First Strand Synthesis System (Invitrogen) according to the manufacturer's instructions. The following primer sequences were used ( Table 1) .
All PCRs were performed in a 10-μl final volume using AmpliTaq Gold PCR Master Mix (Applied Biosystems) with the following amplification conditions: 95 °C for 5 min, and 36 cycles at 94 °C for 30 s, Tm for 40 s and at 70 °C for 30 s. Amplified products were electrophoretically separated on 1.2% agarose gels, and visualized with ethi dium bromide. Bisulfite modification Sodium bisulfite modification was performed using the CpGenome Universal DNA Modification Kit (Chemicon International) according to the manufacturer's protocol. Universally methylated DNA (CpGenome Universal Methylated DNA, Chemicon International) and unmethylated DNA from normal blood samples were treated with bisulfite by the same method.
Bisulfite sequencing
Initially, bisulfite-modified DNA of a target promoter region was amplified. Primer sequences and conditions are shown below in Table 2 . All PCRs were performed in a 20-μl final volume using AmpliTaq Gold PCR Master Mix (Applied Biosystems) with the following amplification conditions: 95 °C for 5 min, and 36 cycles at 94 °C for 30 s, Tm for 40 s and at 70 °C for 2 min and final extension 70 °C for 10 min. Amplified products were electrophoretically separated on 1.2% agarose gels, and visualized with ethidium bromide.
The PCR product was plasmidincorporated using One Shot Escherichia coli cells and the TOPO TA Cloning Kit (Invitrogen Life Technologies Inc). Cells were then plated and grown overnight on prewarmed LB plates containing X-gal, ampicillin and kanamycin. Colony PCR was performed on ten white colonies to validate the insert using primers: M13 Forward: GTAAAACGACG-GCCAG; M13 Reverse: CAGGAAACAGCTAT-GAC. ExoSAP-IT reagent (Affymetrix, USA) was used for PCR Product Cleanup. Preparation for sequencing using SEQ Sequencing Reaction Kit (Montage, USA) according to the manufacturer's protocol. Fragments were sequenced and analysed using Sequencher Software version 4.2. (Gene Codes Corporation, Ann Arbor, MI, USA).
RESULTS
Reverse transcriptase polymerase chain reaction (RT-PCR) is commonly applied to monitor gene expression. By RT-PCR gene expression can be investigated with high accuracy and excellent reproducibility. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) amplification was used as an internal control for cDNA quality and quantity.
Expression array data for COX7A1, KRT81 and SPINT1 genes were verified by RT-PCR using cDNA isolated from 22 snap frozen glioblastoma samples. In addition, we investigated the expression of these genes in cDNA isolated from normal human brain.
Data showed that the housekeeping gene GAPDH was equally expressed in all samples confirming excellent cDNA quality and equal cDNA quantity in these samples. It is noteworthy that COX7A1, KRT81 and SPINT1 revealed a differential expression pattern in the glioblastoma samples (Fig. 1) . Gene expression was decreased in some of the glioblastoma samples. Normal fetal and adult human brain showed robust expression of COX7A1, KRT81 and SPINT1 suggesting that down regulation of these genes in glioblastoma samples was tumor-related. As promoter methylation of these genes might be one possible mechanism of COX7A1, KRT81 and SPINT1 down regulation expression analysis was followed by promoter methylation analysis by bisulfite sequencing.
COX7A1, KRT81 and SPINT1 genes promoter sequences analysis in glioblastoma tumors and control brain
In order to address the possibility of gene regulation by promoter methylation we decided to perform bisulfite sequencing of COX7A1, KRT81 and SPINT1 gene-promoters in selected glioblastoma samples, normal adult human brain and DNA derived from human leucocytes. Bisulfite sequencing allows a precise analysis of methylation in a certain region by converting all non-methylated cytosines into thymine while methylated cytosines remain unchanged. The methylation status of individual cytidine residues in CpG-dinucleotides is then visualized in the sequencing data. The SPINT1 gene promoter region is located on the chromosomal locus 15q15.1. We sequenced a large CpG-island fragment around the transcription start site. The fragment was 344 bp in size and covered 40 CpG-dinucleotides. Bisulfite sequencing results are shown in Fig. 2 .
The analysis of bisulfite-modified DNA of brain tissue confirmed that the SPINT1 promoter had only single scattered methylated CpG-dinucleotides in healthy brain tissue. An unmethylated promoter is compatible with the robust SPINT1 expression in normal human brain.
As can be seen from the bisulfite sequencing results in our investigation of tumor samples SPINT1 promoter methylation was not frequently observed. Samples with high expression of SPINT1 were unmethylated. Glioblastoma samples with low SPINT1 expression accompanied by promoter methylation were observed, however, not very frequently. Nevertheless, our results encourage more detailed analyses of the whole SPINT1 promoter sequence in a larger group of glioma samples to clarify the true relationship between promoter methylation and gene expression.
We sequenced two fragments of the COX7A1 promoter. The first fragment was 309 bp in size and covered 27 CpG-dinucleotides. The second fragment was 349 bp in size and harbored 17 CpG-dinucleotides. Bisulfite sequencing results of these two fragments are shown in Fig. 3 . The two fragments of the COX7A1 promoter exhibited almost complete methylation of all analysed sequence-clones derived from normal human brain. It was decided to investigate the methylation status among different glioblastoma samples. The results revealed that the CpG-islands of the COX7A1 promoter are most abundantly methylated in both glioblastoma samples and normal human brain tissue, irrespective of its gene expression level.
Selected RT-PCR results (alongside)
KRT81 gene promoter region with CpG islands is located on chromosome 12q13. Two potential KRT81 promoter fragments were sequenced around the transcription start site. The first fragment was 324 bp in size and contained 26 CpGdinucleotides. The second fragment was 175 bp in size and harbored also 26 CpG-dinucleotides. Firstly, we sequenced samples of human brain and leucocyte DNA. Bisulfite sequencing results of both fragments are shown in Fig. 4 .
The results revealed that the KRT81 promoter is frequently methylated in leucocytes and normal human brain tissue. We refrained from bisulfite sequencing of the promoter of this gene in glioblastoma tumor samples, as we did not expect that the data could be informative and suitable for future research. The data suggest that the expression of KRT81 is not regulated by promoter methylation in gliomas.
DISCUSSION
Microarray analysis coupled with pharmacologic demethylation of cultured tumor cells is a useful tool for identifying genome-wide epigenetic events and has been successfully implemented for this purpose in other cancer types in the past (Yamashita et al., 2002; Lodygin et al., 2005) . However, genes identified by this method must necessarily be examined in more detail to validate potential epigenetic gene regulation and to elucidate their importance in cancer development. Multiple independent techniques should be implemented to validate these candidate genes. To this end we investigated COX7A1, KRT81 and SPINT1 expression, first in normal human brain tissue. Normal fetal and adult human brain showed robust expression of COX7A1, KRT81 and SPINT1 suggesting that down regulation of these genes in glioblastoma samples was tumor related. Up-regulation of their expression following 5'-aza-dC mediated DNAdemethylation suggested promoter methylation as a mechanism for gene silencing. Surprisingly partial bisulfite sequencing of the COX7A1 and the KRT81 promoter revealed abundant promoter methylation in both normal human brain and glioblastoma samples, irrespective of their individual expression levels. Our results do not fit the classical hypothesis that promoter hypermethylation leads to gene silencing. They might suggest that the expression of these genes might follow other regulations than promoter methylation in gliomas. However, these results might also be explained by other hypotheses. Some reports have shown that histone deacetylase inhibitors (HDACi) produce gene reactivation from hypermethylated promoters without any changes in DNA methylation at the promoter level or that inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation (Raynal et al., 2012; Pruitt et al., 2006) . Another hypothesis suggests that there are some transcription factors that are capable to bind to methylated DNA, i. e. SP1 or NRF1. COX7A1 and KRT81 transcription might be regulated by one of these transcription factors, explaining their expression despite methylated promoter sequences (Harrington et al., 1988; Smith et al., 2004) . The third hypothesis relates to the bisulfite sequencing method itself. Bisulfite sequencing cannot discriminate 5-methylcytosine from 5-hydroxymethylcytosine. The recent discovery that the three members of the TET protein family can convert 5-methylcytosine (5 mC) into 5-hydroxymethylcytosine (5 hmC) has provided a potential mechanism leading to DNAdemethylation (Williams et al., 2012; Branco et al., 2012) . Maybe in our result we detected not 5 mC but rather 5 hmC. All these hypotheses have to be addressed by investigations in future in order to elucidate the functional contribution of these genes to gliomagenesis.
CONCLUSIONS
COX7A1 and KRT81 expression is independent of promoter methylation in glioblastoma. The data encourage extended promoter methylation analysis of SPINT1 in order to elucidate its potential as a molecular glioblastoma marker.
